Results from US Government-Sponsored Phase 1 Trial of VSV Vaccine Reported
?An early-stage clinical trial of an experimental Ebola vaccine conducted at the National Institutes of Health (NIH) and the Walter Reed Army Institute of Research (WRAIR) found that the vaccine, called VSV-ZEBOV, was safe and elicited robust antibody responses in all 40 of the healthy adults who received it. The most common side effects were injection site pain and transient fever that appeared and resolved within 12 to 36 hours after vaccination. A report describing preliminary results of the NIH-WRAIR study appears online today in The New England Journal of Medicine. The VSV-ZEBOV candidate is one of two experimental Ebola vaccines now being tested in the phase 2/3 PREVAIL clinical trial that is enrolling volunteers in Liberia.
“The ongoing Ebola outbreak in West Africa is unprecedented in scope and duration,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID), part of the NIH. “The outbreak is slowly coming under control, thanks to extraordinary and multi-faceted efforts in the affected nations. However, there still are no licensed specific therapies or vaccines for Ebola. Until a safe and effective vaccine is available, the world will continue to be under-prepared for the next Ebola outbreak.”
Scientists at the Public Health Agency of Canada developed the candidate vaccine. It was licensed to NewLink Genetics Corp. of Ames, Iowa, a company collaborating with Merck & Co. Inc., of Kenilworth, New Jersey, which is responsible for advancing this vaccine towards regulatory approval. The investigational vaccine is based on a genetically modified and attenuated vesicular stomatitis virus (VSV), a virus that mainly affects cattle. In the investigational vaccine, a gene for a VSV protein is replaced with a gene segment from a key protein in the Zaire species of Ebola virus. The vaccine does not contain the whole Ebola virus and therefore cannot infect vaccinated persons with Ebola.
The new report summarizes results of the first 52 volunteers enrolled in the study: 26 at the NIH Clinical Center in Bethesda, Maryland, and 26 at the WRAIR clinic in Silver Spring, Maryland. Six volunteers at each site received a placebo injection of saline solution, and the remaining 40 received the experimental vaccine at either one of two different dosages (2 x107 or 3 x106 in 20 volunteers at each site). The NIH trial was led by NIAID investigators Richard T. Davey, Jr., M.D., and John H. Beigel, M.D., while Jason A. Regules, M.D., and Stephen J. Thomas, M.D., headed the trial at WRAIR.
The candidate vaccine’s ability to stimulate immune responses was assessed by sampling the volunteers’ blood at multiple time points following injection. (The blood sampling schedule differed between the two trial sites.) Of those volunteers tested at 14 days after injection, 93 percent (26 out of 28) of whose who had received vaccine developed antibodies against Zaire species of Ebola virus. Antibodies were detected in the remaining 14 volunteers who had received vaccine by 28 days after injection. Antibody responses were approximately three-fold greater in those who received the higher vaccine dose. This information was available to the designers of the PREVAIL trial and was used to guide the decision to use VSV-ZEBOV at the higher dosage level in that trial.
“The prompt, dose-dependent production of high levels of antibodies following a single injection and the overall favorable safety profile of this vaccine make VSV-ZEBOV a promising candidate that might be particularly useful in outbreak interventions,” said Dr. Davey.
Read more: Experimental Ebola Vaccine Safe, Prompts Immune Response
The Latest on: Ebola Vaccine
[google_news title=”” keyword=”Ebola Vaccine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Ebola Vaccine
- Snakebite alert; 9,900 cases recorded annuallyon April 27, 2024 at 7:11 am
The country recorded 59,600 snakebite cases between 2015 and 2020, the first time such data has been put together.
- COVID may have eroded doctors' belief that they are obligated to treat infectious patientson April 25, 2024 at 12:22 pm
A systematic review posted in Clinical Infectious Diseases reveals that, amid the COVID-19 pandemic, many physicians felt less ethically obligated to provide care to infectious-disease patients if ...
- 20 Fastest Growing Health Tech Companies in the Worldon April 25, 2024 at 8:34 am
In this article, we will be taking a look at the 20 fastest growing health tech companies in the world. If you do not want to learn about the trends in digital health market, head straight to the 5 ...
- Over 50mln lives saved in Africa through expanded immunisation programme — WHOon April 25, 2024 at 4:28 am
An estimated 51.2 million lives have been saved through vaccines in the African region over the past 50 years. For every infant life saved over that period, close to 60 years of life are lived, a new ...
- What is the flu virus likely to cause the next pandemic?on April 23, 2024 at 6:35 am
A new survey of 187 scientists set to be published at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) congress in Barcelona says that the flu virus, also known as ...
- This Kenya Cave, Believed To Be Source Of Ebola, Could Cause Next Pandemicon April 22, 2024 at 9:11 am
The 600-foot-deep cave has been continuously dug and expanded by elephants, only to have disease-carrying bats make it their home.
- The Essential Program on Immunization is 50: Milestones, achievements, and future directionson April 22, 2024 at 7:37 am
Each year, the World Health Organization (WHO) partakes in World Immunization Week, a period of reflection, raising awareness, and future planning surrounding global action required to combat ...
- Biotech Matters: Public-Private Coordination of Biotechnologyon April 16, 2024 at 5:01 pm
While there are great challenges ahead for public-private alignment around biotechnology, they can be overcome by accurately appraising the obstacles to public-private collaboration, and in doing so, ...
- Man Who Caught Virus From A Monkey In A Critical Condition B Virus Explainedon April 16, 2024 at 9:20 am
It is a biosafety category 4 virus , the highest level – the same as Ebola and unknown new pathogens ... If not treated promptly, it has a mortality rate of 70% . There is no vaccine against this ...
- Biden administration announces new partnership with 50 countries to stifle future pandemicson April 15, 2024 at 5:00 pm
But major disputes have emerged over vaccine equity and transferring the technology used ... globe have been overwhelmed with COVID-19 and other health emergencies such as Ebola, malaria and mpox, the ...
via Bing News